" class="no-js "lang="en-US"> Robbie Woodman - Medtech Alert
Thursday, October 09, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Robbie Woodman

Robbie Woodman

About Robbie Woodman

Rob joined TVI as Senior Partner in 2018. In addition to serving as Board Director or Observer at the Board of seven TVI portfolio companies, Rob led the formation and fundraising for TranSINE Therapeutics. Prior to joining TVI, Rob was Director of Healthcare Investments at Touchstone Innovations, and he was central to the formation of a number of now well-established UK biotech companies including Mission Therapeutics, Crescendo Therapeutics and Storm Therapeutics.

Related Story

Appointments

 Transine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO | Pharmtech Focus

Transine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO

July 5 2021

Transine Therapeutics, a biotechnology company developing a novel class of therapeutic RNAs based on its […]